logo
Plus   Neg
Share
Email

Merck Says Phase 3 KEYTRUDA Trial Meets Primary Endpoint

Merck (MRK) Monday said its KEYTRUDA anti-PD-1 therapy for surgically resected high-risk melanoma met the primary endpoint of recurrence-free survival. The company, known as MSD outside the US, said phase 3 randomized, double-blind EORTC1325/KEYNOTE-054 trial resulted in significantly longer recurrence-free survival than placebo. The study will continue in order to evaluate other key endpoints, including overall survival.

Merck plans to present the results at an upcoming medical meeting.
In total, the study enrolled 1,019 patients who were randomly assigned to receive either KEYTRUDA at a flat dose of 200 mg intravenously on day 1 of each 21-day cycle for up to 1 year or placebo IV on day 1 of each 21-day cycle for up to 1 year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss banking giant UBS Group AG reported Monday higher profit in its first quarter with increased net interest income. The company said it has had an excellent start to 2018. However, UBS shares were trading around 3 percent lower in Switzerland. All of UBS's businesses are affected by economic growth expectations, interest rates, equity market levels and foreign exchange rates. Walmart is ditching its dress code policy and is testing a new dress code that will allows "associates" to wear blue denim and shirts of any solid color. The updated dress coded guidelines now allow employees to wear blue "jeggings" and blue jeans and shirts of any solid color, according to a Walmart... Canadian investment firm Fairfax Financial Holdings Ltd. has submitted a "stalking horse" bid worth C$300 million, or $237 million, for the Canadian unit of Toys "R" Us, according to court documents. A stalking horse bid is an initial bid on the assets of a bankrupt company. The bankrupt company will choose an entity from a pool of bidders who will make the first bid on its assets.
Follow RTT